MARCO and CD163 mRNA expression in PDAC tissues is a negative prognostic marker for pancreatic cancer after surgery [68], and the application of anti-bodies against MARCO may present itself as an attractive therapeutic approach to remodel the TME towards susceptibility to immunotherapies [69]. This evidence concerns the gene CD163 and pancreatic neoplasm.